Curatis Holding AG (LON:0QNS)

London · Delayed Price · Currency is GBP · Price in CHF

19.20

+0.45 (2.40%)

At close: Sep 25, 2026

Market Cap	92.73M +49.9%
Revenue (ttm)	12.59M +32.8%
Net Income	-613.78K
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4
Open	19.20
Previous Close	18.75
Day's Range	19.20 - 19.20
52-Week Range	10.53 - 22.78
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Sep 30, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage... [Read more]

Industry Pharmaceutical Preparations

Founded 2002

Employees 9

Stock Exchange London Stock Exchange

Ticker Symbol 0QNS

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.

Financial numbers in CHF Financial Statements